Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest Low molecular weight heparin Stories

2014-03-28 08:22:23

DUBLIN, Mar. 28, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/xvt3hx/investigation ) has announced the addition of the "Investigation Report on China Enoxaparin Sodium Market, 2009-2018" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Thrombosis is the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system. It can result in anoxia, the complete deprivation of...

2014-03-14 08:22:46

DUBLIN, Mar. 14, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/zv5f56/china_heparin ) has announced the addition of the "Concise Analysis of the Chinese Heparin Industry" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe's total) and heparin APIs are...

2014-02-28 14:07:10

Low-molecular-weight heparin is commonly used in surgeries to prevent dangerous blood clots. But when patients experience the other extreme – uncontrolled bleeding – in response to low-molecular-weight heparin, there is no antidote. Now researchers at the University of North Carolina at Chapel Hill and Rensselaer Polytechnic Institute have created a synthetic form of low-molecular-weight heparin that can be reversed if things go wrong and would be safer for patients with poor kidney...

2013-12-09 08:29:05

- VTE patients with cancer treated with once-daily edoxaban had a numerically lower incidence of recurrent VTE and a 36% lower risk of clinically relevant bleeding compared to warfarin in a subgroup analysis of the phase 3 Hokusai-VTE study(1) NEW ORLEANS and TOKYO, Dec. 9, 2013 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced results of a prespecified subgroup analysis of 771 cancer patients enrolled in the phase 3 Hokusai-VTE study. Patients with...

2013-11-08 23:04:39

A new study just published online in The Oncologist shows that outpatients receiving chemotherapy are at high risk of developing venous thromboembolism (VTE) and of major bleeding complications, especially those with pancreas, stomach and lung cancer. The authors therefore conclude that thromboprophylaxis, or blood thinning treatments, should be considered for such patients, after carefully assessing the risks and benefits of treatment. Durham, NC (PRWEB) November 08, 2013 A large-scale...

2013-10-10 23:19:31

ChinaMarketResearchReports.com adds latest report on “China Heparin Industry Report, 2013-2015” to its store. Entry barrier, global market supply & demand, competition pattern, forecast, etc. of heparin industry in China. Dallas, TX (PRWEB) October 10, 2013 Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradually recognized...

2013-08-29 12:25:33

The Markets for Both VTE Primary Prophylaxis and VTE Treatment/Secondary Prophylaxis Will Grow to $7.3 Billion in 2022, According to a New Report from Decision Resources BURLINGTON, Mass., Aug. 29, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that Bayer/Janssen's Xarelto will be the sales-leading therapy among the novel oral anticoagulants in the combined venous thromboembolism...

2012-11-20 08:25:43

DALLAS, November 20, 2012 /PRNewswire/ -- - RnRMarketResearch.com adds new market research reports "Antithrombotic / Anticoagulant Drugs: Technologies and Global Markets" to its store. This report provides an overview of the global market for antithrombotic/anticoagulant drugs, which is changing due to factors such as an aging population, an increase in thrombotic events, and recent advances in pharmaceuticals. Analyses of global market trends, with data from 2011,...

2012-08-02 23:02:49

Protection of Global Heparin Supply Focus of International Meeting Rockville, Md (PRWEB) August 02, 2012 As part of its role in ongoing efforts to better safeguard the global supply of medicines, the U.S. Pharmacopeial Convention (USP) will co-host the “Fifth Workshop on the Characterization of Heparin Products” at its U.S. headquarters in Rockville, Md., August 14-15, 2012. Since 2008, USP´s workshop on heparin products has provided a forum for manufacturers, regulators...

2012-05-23 20:44:01

Third round of improvements to blood thinner standard announced by USP To help further secure a safe supply of the widely—used blood thinner heparin, a third round of revisions to quality standards for the drug has been advanced by the U.S. Pharmacopeial Convention (USP). USP's Expert Panel on Unfractionated Heparin ended a two-day meeting on May 16th, 2012, and recommended finalization of the proposed changes. The revisions are scheduled to appear in the November—December 2012...